Burcugül Kaya

Burcugül Kaya

Auto-generated profile, based on publicly available information

Burcugül Kaya

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Emniyet Mahallesi, Mevlana Bulvarı, No: 29, Yenimahalle, 06560, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in European Journal of Rheumatology
Verified
Journal Article
Open access
DYDerya Yıldırım
Derya Yıldırım
RKRıza Can Kardaş
Rıza Can Kardaş
BÖBurcugul Özkızıltaş
Burcugul Özkızıltaş
IVİbRahim Vasi
İbRahim Vasi
HKHamit Kucuk
Hamit Kucuk
ATABDURRAHMAN TUFAN
ABDURRAHMAN TUFAN
Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases. Cite this article as: Yıldırım D, Kardaş RC, Özkızıltaş B, et al. Dual biologic therapy in patients with familial mediterranean fever and spondyloarthritis: case-based review. Eur J Rheumatol 2023;10(1):29-33.

28 October 2025 in Rheumatology
Verified
Journal Article
Closed access
IVİbRahim Vasi
İbRahim Vasi
IKİbRahim Karaduman
İbRahim Karaduman
ŞAŞeyma Alacaoğlu
Şeyma Alacaoğlu
SDSerra Duygulu
Serra Duygulu
RKRıza Can Kardaş
Rıza Can Kardaş
AEAbdulsamet Erden
Abdulsamet Erden
Objectives: Cardiopulmonary involvement is the leading cause of mortality in SSc, and early detection of interstitial lung disease (ILD) is critical to improving outcomes. Conventional spirometry has limitations, whereas impulse oscillometry (IOS) could provide a non-invasive, effort-independent method to detect and monitor pulmonary involvement in these patients. We aimed to evaluate IOS parameters in SSc-ILD, comparing their performance with conventional spirometry. Methods: This study assessed the detection of the presence and severity of ILD in SSc patients using conventional spirometry, diffusing lung capacity for carbon monoxide (DLCO), IOS, and high-resolution CT (HRCT). Results: Among 66 SSc patients, ILD was identified in 62.1%, with 26 patients having extensive and 15 limited ILD on HRCT. IOS demonstrated higher mean resonant frequency (Fres) in ILD-positive patients than in ILD-negative patients (22.95 ± 5.47 vs 15.01 ± 6.01, P = 0.001). Fres was also significantly higher in extensive ILD than in limited ILD and ILD-negative groups (P = 0.001 and P = 0.011, respectively). ROC analysis demonstrated that Fres achieved comparatively better diagnostic accuracy for detecting extensive ILD [area under the curve (AUC): 0.841, cut-off: 22.35, sensitivity: 73.1%, specificity: 85%], outperforming forced vital capacity (FVC) (% predicted) and DLCO (% predicted). For limited ILD, Fres showed moderate diagnostic performance (AUC: 0.752, cut-off: 17.42, sensitivity: 80%, specificity: 64%). Conclusion: Our findings indicate that impulse oscillometry, particularly Fres, may provide a non-invasive and effort-independent approach to assessing interstitial lung disease in SSc. Fres appeared to be related to radiological ILD extent and showed some diagnostic value, including in cases less evident by conventional spirometry.

19 March 2025 in Wiener klinische Wochenschrift
Verified
Journal Article
Open access
RDRahime Duran
Rahime Duran
DYDerya Yıldırım
Derya Yıldırım
RKRıza Can Kardaş
Rıza Can Kardaş
IVİbRahim Vasi
İbRahim Vasi
BKBurcugül Kaya
Burcugül Kaya
AEAbdulsamet Erden
Abdulsamet Erden
Summary: Background: Systemic lupus erythematosus is a multisystem autoimmune disease primarily manifesting as lupus nephritis. While lupus nephritis is the most common renal pathology in lupus, non-lupus nephropathies such as IgA nephropathy occasionally occur. This study aims to evaluate the clinical features and outcomes of lupus patients with IgA nephropathy, comparing them with those of primary IgA nephropathy and lupus nephritis. Methods: A comprehensive literature review was conducted using the PubMed and Google Scholar databases to identify cases of systemic lupus erythematosus with IgA nephropathy reported between 1995 and December 2023. A total of 16 cases were identified and 2 additional cases from our clinic were included. These cases were compared with 47 lupus nephritis patients from our clinic and 215 primary IgA nephropathy patients from the literature. Data were collected on demographics, serology, renal biopsy findings, treatment, progression to renal failure and mortality. Results: We identified 18 cases of lupus with IgA nephropathy with a median age of 41.6 years and a female predominance (72.2%). In comparison to the primary IgA nephropathy cohort, lupus with IgA nephropathy group exhibited a lower rate of renal failure (11.1% vs. 34%) and mortality (5.6% vs. 20%). Additionally, the lupus-IgA nephropathy group showed a slightly lower mortality rate compared to the lupus nephritis cohort (5.6% vs. 10.6%). Conclusion: Lupus with predominantly IgA deposits often follows a more indolent course than primary IgA nephropathy but severe cases with crescentic glomerulonephritis can still progress to renal failure.

13 June 2025 in Bratislava Medical Journal
Verified
Journal Article
Open access
PDF file
HKHandenur Koç Kanık
Handenur Koç Kanık
AEAbdulsamet Erden
Abdulsamet Erden
DYDerya Yıldırım
Derya Yıldırım
AKArif Burak Kanık
Arif Burak Kanık
RDRahime Duran
Rahime Duran
BGBerna Göker
Berna Göker
Objective: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse patterns of organ involvement, morbidity, and mortality. This study aimed to assess changes in demographic, clinical, and therapeutic characteristics of a single-center SLE cohort over the last two decades. Materials and methods: This retrospective study included 409 SLE patients from the Rheumatology Department at Gazi University Faculty of Medicine, meeting the 2019 EULAR/ACR classification criteria. Patients were categorized by diagnosis year into two groups: 1987–2012 and 2013–2023. Results: The proportion of male SLE patients increased approximately 2.5-fold in the last decade (5.2% vs. 12.6%, p = 0.008). While lupus nephritis rates remained stable, neurological (p = 0.012), hematological (p < 0.001), pulmonary (p < 0.001), and gastrointestinal (p < 0.001) involvements were significantly higher in the last decade. Use of mycophenolate mofetil (p = 0.036), methotrexate (p < 0.001), calcineurin inhibitors (p < 0.001), and rituximab (p < 0.001) increased, while steroid use (p = 0.044) and flare frequency (p = 0.035) decreased significantly. Although crude mortality rates improved (4.7% vs. 3.5%) without statistical significance (p = 0.54), male patients exhibited higher mortality rates than females (13.8% vs. 3.2%, p = 0.011). Hospitalization rates decreased but were not statistically significant (0.00130 vs. 0.00104/patient/year, p = 0.855). Conclusion: Over the last two decades, SLE management has evolved with improved therapeutic approaches and changing clinical manifestations. However, mortality remains disproportionately higher in male patients, underscoring the need for targeted interventions.

1 January 2025 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
IVİbRahim Vasi
İbRahim Vasi
RKRıza Can Kardaş
Rıza Can Kardaş
KTKaan Talay
Kaan Talay
DYDerya Yıldırım
Derya Yıldırım
BKBurcugül Kaya
Burcugül Kaya
AEAbdulsamet Erden
Abdulsamet Erden
Background/Aim: Moyamoya disease, a rare cerebrovascular disorder first identified in Japan, is characterised by spontaneous occlusion of the circle of Willis and is a significant cause of ischaemic and haemorrhagic strokes. When associated with autoimmune disorders like antiphospholipid syndrome, it is referred to as moyamoya syndrome. This study reviews the clinical features of moyamoya syndrome in patients with antiphospholipid antibody positivity, with and without antiphospholipid syndrome, focusing on clinical differences, treatments and outcomes. Methods: To identify relevant studies, a comprehensive systematic literature review search was conducted using the terms ‘Moyamoya’, ‘antiphospholipid’, ‘anticardiolipin antibodies’, ‘anti‐beta2‐glycoprotein I antibodies’ and ‘lupus anticoagulant’. Results: Twelve cases of moyamoya syndrome with antiphospholipid antibody positivity were reviewed. Eight met antiphospholipid syndrome criteria with diverse antibody profiles. Treatments included antiplatelet therapy, anticoagulants and bypass surgery. While eight patients experienced no recurrent strokes during follow‐up, three had recurrent strokes, and two died from haemorrhagic events. Individualised management was crucial for balancing treatment benefits and risks. Discussion: Moyamoya disease involves internal carotid artery stenoses, also seen in antiphospholipid syndrome. While the connection between moyamoya disease and antiphospholipid antibody positivity remains unclear, antiphospholipid syndrome should be ruled out during diagnosis. Surgical treatments are less frequent in antiphospholipid antibody‐positive patients than in general moyamoya disease. Recurrent cerebrovascular events under medical treatment highlight the potential need for broader surgical interventions in these patients. Conclusion: The limited number of reported cases restricts the generalisability of the current findings and calls for cautious interpretation. This underlines the need for further multicentre studies and randomised trials to optimise therapeutic strategies, elucidate the role of antiphospholipid antibodies and establish evidence‐based guidelines for the management of moyamoya syndrome and its variants.

12 June 2026 in Rheumatology International
Verified
Journal Article
Closed access
RKRıza Can Kardaş
Rıza Can Kardaş
DYDerya Yıldırım
Derya Yıldırım
BKBurcugül Kaya
Burcugül Kaya
IVİbRahim Vasi
İbRahim Vasi
RDRahime Duran
Rahime Duran
MÖM. Akif Öztürk
M. Akif Öztürk